CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Orally Disintegrating Tablet Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, ...
Rockville, MD, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Based on a new research report published by Fact.MR, the global orally disintegrating tablet market is poised to reach a valuation of US$ 24.45 billion ...
This article is part of PharmTech's supplement "API Synthesis and Formulation 2009." New drug-delivery technologies are often championed by contract manufacturing organizations. For new technologies ...
UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals. SPI Pharma introduced an excipient platform for flash orally disintegrating tablets ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently approved Adzenys XR-ODT for the treatment of attention ...
Zolmitriptan 2.5mg, 5mg; orange flavor; contains phenylalanine. Store Zomig Tablets and zolmitriptan orally disintegrating tablets at controlled room temperature, 20 - 25ºC (68 - 77ºF) [see USP].
MALVERN, Pa., Nov. 18, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback